ANAHEIM, CA, Dec. 14, 2017 (GLOBE NEWSWIRE) -- BioCorRx Inc.(BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addiction, today announced that it has entered into an agreement with the National Institute on Alcohol Abuse and Alcoholism (NIAAA). As noted on their website, “NIAAA is one of the 27 institutes and centers that comprise the National Institutes of Health (NIH). NIAAA supports and conducts research on the impact of alcohol use on human health and well-being. It is the largest funder of alcohol research in the world.” The purpose of the agreement is to share information and potentially collaborate on further research, development and commercialization of the Company’s therapies and programs for the treatment of alcohol use disorder.
Brady Granier, CEO, President, and Director of BioCorRx(BICX), commented, “We are pleased to have another important government agency interested in our naltrexone implant, BICX102. NIAAA leads the national effort to reduce alcohol-related problems and we are happy to engage with them in preparation for our Pre-IND meeting next January. Naltrexone is already approved in other forms for the treatment of alcohol and opioid use disorders and our desire is to gain approval for both indications for BICX102. We look forward to exploring the opportunities for collaborating with NIAAA on this important product. Alcohol use disorder is a very large issue that often gets lost in the current opioid epidemic. It needs more attention and options for treatment.”
About BioCorRx(BICX)
